The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Jan 2022
Randomized Controlled Trial Multicenter Study Comparative StudyNivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1-2 CheckMate 040 study. We aimed to investigate nivolumab monotherapy compared with sorafenib monotherapy in the first-line setting for patients with advanced hepatocellular carcinoma. ⋯ Bristol Myers Squibb in collaboration with Ono Pharmaceutical.